ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,277.51
0.80%
US Tech 100
18,064.80
0.02%
다우존스 지수
38,686.32
1.51%
Bitcoin
68,140.52
0.61%
Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Revelation Biosciences Inc (REVB)

  7. Revelation Biosciences Inc (REVB) 뉴스

REVB

Revelation Biosciences (REVB)

Revelation Biosciences Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:REVB
일자시간출처헤드라인심볼기업
2024/05/1105:52Business WireRevelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024NASDAQ:REVBRevelation Biosciences Inc
2024/03/2305:15Business WireRevelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023NASDAQ:REVBRevelation Biosciences Inc
2024/03/1322:00Business WireRevelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024)NASDAQ:REVBRevelation Biosciences Inc
2024/03/1222:00Business WireRevelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth ConferenceNASDAQ:REVBRevelation Biosciences Inc
2024/03/0423:00Business WireRevelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of GeminiNASDAQ:REVBRevelation Biosciences Inc
2024/02/1410:12Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:REVBRevelation Biosciences Inc
2024/02/1323:00Business WireRevelation Biosciences Inc. Receives Invitation to Give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)NASDAQ:REVBRevelation Biosciences Inc
2024/02/1300:19Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:REVBRevelation Biosciences Inc
2024/02/0906:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:REVBRevelation Biosciences Inc
2024/02/0606:41Business WireRevelation Biosciences Inc. Announces Closing of $6.2 Million Public OfferingNASDAQ:REVBRevelation Biosciences Inc
2024/02/0306:06Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:REVBRevelation Biosciences Inc
2024/02/0120:00Business WireRevelation Biosciences Inc. Announces Pricing of $6.2 Million Public OfferingNASDAQ:REVBRevelation Biosciences Inc
2024/02/0114:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:REVBRevelation Biosciences Inc
2024/01/3107:21Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:REVBRevelation Biosciences Inc
2024/01/3105:32Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:REVBRevelation Biosciences Inc
2024/01/3023:00Business WireRevelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)NASDAQ:REVBRevelation Biosciences Inc
2024/01/3007:32Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:REVBRevelation Biosciences Inc
2024/01/2406:18Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:REVBRevelation Biosciences Inc
2024/01/2323:00Business WireRevelation Biosciences Inc. Announces 1-for-30 Reverse Stock Split Effective January 25, 2024NASDAQ:REVBRevelation Biosciences Inc
2024/01/2306:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:REVBRevelation Biosciences Inc
2023/12/2307:06Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:REVBRevelation Biosciences Inc
2023/12/2303:23Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:REVBRevelation Biosciences Inc
2023/12/1306:59Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:REVBRevelation Biosciences Inc
2023/11/1406:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:REVBRevelation Biosciences Inc
2023/11/1406:05Business WireRevelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2023NASDAQ:REVBRevelation Biosciences Inc
2023/11/1006:07Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:REVBRevelation Biosciences Inc
2023/10/1305:26Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:REVBRevelation Biosciences Inc
2023/10/1222:00Business WireGemini Induces Pharmacologic Activity and Related Physiologic Changes in Multiple Preclinical StudiesNASDAQ:REVBRevelation Biosciences Inc
2023/10/0422:00Business WireRevelation Biosciences, Inc. to Present at the 2023 ROTH Healthcare Opportunities ConferenceNASDAQ:REVBRevelation Biosciences Inc
2023/10/0305:24Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:REVBRevelation Biosciences Inc
 검색 관련기사 보기:NASDAQ:REVB

최근 히스토리

USOTC
ADDYY
Adidas (QX)
FX
USDEUR
US Dollar vs Euro
NASDAQ
AMZN
Amazon.com
USOTC
RHHBY
Roche (QX)
USOTC
BNPQY
BNP Paribas (QX)
NYSE
MCD
McDonalds
FX
USDJPY
US Dollar vs Yen
NYSE
MRK
Merck
COIN
ETHUSD
Ethereum
CCOM
US30
US 30
CCOM
SILVER
SILVER
NASDAQ
GOOGL
Alphabet
NASDAQ
TSLA
Tesla
NYSE
KO
Coca Cola
CCOM
US500
US 500
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유